A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors

While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates remain modest and outcomes vary with no clinically useful bioma...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European urology oncology 2021-06, Vol.4 (3), p.464-472
Hauptverfasser:	Khaki, Ali Raza, Li, Ang, Diamantopoulos, Leonidas N., Miller, Natalie J., Carril-Ajuria, Lucia, Castellano, Daniel, De Kouchkovsky, Ivan, Koshkin, Vadim, Park, Joseph, Alva, Ajjai, Bilen, Mehmet A., Stewart, Tyler, Santos, Victor, Agarwal, Neeraj, Jain, Jayanshu, Zakharia, Yousef, Morales-Barrera, Rafael, Devitt, Michael, Nelson, Ariel, Hoimes, Christopher J., Shreck, Evan, Gartrell, Benjamin A., Sankin, Alex, Tripathi, Abhishek, Zakopoulou, Roubini, Bamias, Aristotelis, Rodriguez-Vida, Alejo, Drakaki, Alexandra, Liu, Sandy, Kumar, Vivek, Lythgoe, Mark P., Pinato, David J., Murgic, Jure, Fröbe, Ana, Joshi, Monika, Isaacsson Velho, Pedro, Hahn, Noah, Alonso Buznego, Lucia, Duran, Ignacio, Moses, Marcus, Barata, Pedro, Galsky, Matthew D., Sonpavde, Guru, Yu, Evan Y., Shankaran, Veena, Lyman, Gary H., Grivas, Petros
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Bladder cancer Carcinoma, Transitional Cell - drug therapy Cohort Studies Female Humans Immune Checkpoint Inhibitors Immunotherapy Outcome research Prognosis Prognostic model Retrospective Studies Urinary Bladder Neoplasms - drug therapy Urothelial carcinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!